On December 10, 2021, Asymchem was successfully listed on the Hong Kong Stock Exchange, raising a total of approximately HK$7,145 million.
Goldman Sachs and CLSA acted as joint sponsors of the offering.
CYL & Partners, Cooley and DeHeng Law Offices provided legal services to the issuer in respect of Hong Kong law, US law and PRC law respectively.
Latham & Watkins LLP and Jun He Law Offices provided legal services to the joint sponsors in respect of Hong Kong and U.S. law and PRC law respectively.
Ernst & Young acted as the auditor and reporting accountant for the offering.
Asymchem is a CDMO company that provides one-stop services for the development and production of high-quality new drugs worldwide. Prior to that, Asymchem was listed on the main board of Shenzhen Stock Exchange in 2016.